Estradiol Cypionate
FDA-approved product (injectable, injection), marketed as Depo-Estradiol, Estradiol Cypionate.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Atrophic Vaginitis
- Atrophy
- Breast cancer
- Breast carcinoma
- Breast neoplasm
- Dyspareunia
- Hypogonadism
- Menopause
- Osteoporosis
- Postmenopausal atrophic vaginitis
- Postmenopausal osteoporosis
- Premature ovarian insufficiency
- Primary ovarian insufficiency
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Natural and semisynthetic estrogens, plain
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA56.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae23.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Estradiol Cypionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
NCT00099437 · start 2005-02-13
Registered record
- Registry ID
- NCT00099437
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2005-02-13
- Completion
- 2026-12-31
- Enrolment
- 736
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionFulvestrantPhasePhase 3Registry statusActive not recruitingFulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
NCT00146601 · start 2004-06
Registered record
- Registry ID
- NCT00146601
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-06
- Completion
- 2007-07
- Enrolment
- 35
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast CancerInterventionFulvestrantPhasePhase 2Registry statusCompletedAdministration of Oral Contraceptives at Different Times of the Follicular Phase of the Menstrual Cycle
NCT00204438 · start 2002-02
Registered record
- Registry ID
- NCT00204438
- Conditions
- Contraception
- Interventions
- 0.15mg desogestrel /0.03mg ethinyl estradiol
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2002-02
- Completion
- 2002-12
- Enrolment
- 45
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionContraceptionIntervention0.15mg desogestrel /0.03mg ethinyl estradiolPhaseNot applicableRegistry statusCompletedHormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer
NCT00003771 · start 1997-09
Registered record
- Registry ID
- NCT00003771
- Conditions
- Breast Cancer; Menopausal Symptoms
- Interventions
- therapeutic estradiol; norethindrone acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1997-09
- Completion
- 2004-02
- Enrolment
- 1,300
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Cancer; Menopausal SymptomsInterventiontherapeutic estradiol; norethindrone acetatePhasePhase 3Registry statusCompletedPaclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00021372 · start 1996-02
Registered record
- Registry ID
- NCT00021372
- Conditions
- Lymphoma
- Interventions
- estramustine phosphate sodium; paclitaxel
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1996-02
- Completion
- 2006-09
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLymphomaInterventionestramustine phosphate sodium; paclitaxelPhasePhase 2Registry statusCompleted